Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Buy” by Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $196.75.

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Citigroup reissued a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, HC Wainwright increased their price objective on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jamison Private Wealth Management Inc. purchased a new position in shares of Krystal Biotech during the 2nd quarter worth approximately $28,000. GAMMA Investing LLC grew its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc bought a new position in Krystal Biotech in the second quarter worth $28,000. Blue Trust Inc. lifted its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Quest Partners LLC purchased a new position in Krystal Biotech during the second quarter valued at $71,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Stock Down 0.7 %

Shares of KRYS stock opened at $177.14 on Monday. The business has a 50-day moving average price of $192.47 and a two-hundred day moving average price of $179.64. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The firm has a market cap of $5.06 billion, a P/E ratio of 94.73 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.25) earnings per share. As a group, research analysts expect that Krystal Biotech will post 3.13 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).